PRESS RELEASE

MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026

Rellingen, 27 January 2026 – On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for Infection Research (HZI) in Braunschweig.

The focus of the event will be the presentation and scientific classification of a groundbreaking cold plasma therapy for application in the lungs. For Viromed stakeholders, the findings are of high strategic relevance, as they address a medical field in which there is an urgent and, to date, insufficiently met clinical need worldwide: severe pulmonary infections – particularly in vulnerable patient groups and in intensive care settings.

The relevance of the topic is driven in particular by three key factors:

• High global disease burden: Pulmonary infections and associated complications affect millions of patients worldwide every year and represent one of the major challenges of modern acute and intensive care medicine.
• Growing therapeutic limitations: The increasing prevalence of antibiotic-resistant pathogens further exacerbates the situation and intensifies the pressure to develop new and effective therapeutic approaches.
• New physical treatment option: The planned publication of an innovative physical therapy principle for the lungs potentially represents a paradigm shift in infection treatment and opens up the prospect of scalable clinical application.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de
 

Press contact

E-mail: viromed@kirchhoff.de

Frauenfeld, 26 January 2026

Press release

DocMorris repurchases convertible bonds maturing in 2026 with a nominal value of around CHF 14.4 million

DocMorris Finance B.V. has agreed with a holder of 2026 convertible bonds to purchase an aggregate nominal amount of around CHF 14.4 million. The purchase is expected to be settled in the coming days. The completion of the purchase and the immediate cancellation will reduce the total outstanding aggregate nominal amount to less than CHF 8.0 million from the original CHF 95.0 million.

Investors and analyst contact
Lisa Lüthi, Senior Investor Relations Manager
Email: ir@docmorris.com

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving 11 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Media Information

Dr. Christian Schlögel nominated as new member of the Board of Directors

Allschwil, January 26, 2026 – The Board of Directors of SKAN Group AG proposes Dr. Christian Schlögel as a new member for election at the Annual General Meeting on May 7, 2026. Patrick Schär will not stand for re-election after 16 years on the Board of Directors.

Dr. Christian Schlögel (born 1964, German citizen) is a proven expert in software, digital transformation and artificial intelligence with 30 years of leadership experience in global technology, software and industrial companies. From 2018 to 2025, he was Group Chief Digital Officer and member of the Executive Board of Körber AG, where he was responsible for the digital transformation of the group with around 14,000 employees. From 2014 to 2018, he was Group Chief Technology & Digital Officer at KUKA AG, an international automation and robotics group with around 15,000 employees. He currently contributes his expertise as a member of administrative and advisory boards at various companies. Christian Schlögel started his professional career at SAP AG. He holds a degree in computer science from the Karlsruhe Institute of Technology and a doctorate in business administration from the University of Passau.

Beat Lüthi, Chairman of the Board of Directors of the SKAN Group, explained: “SKAN expands its offering to include software and digital integration services, for which we acquired a majority stake in Metronik last year. In parallel, we are driving forward the digital transformation of the company and our services. Christian Schlögel can significantly support these initiatives, which are core elements of the strategy for future sales and margin growth, with his expertise. The Board of Directors is therefore delighted to be able to propose him for election to the shareholders.

Patrick Schär has decided not to stand for re-election to the Board of Directors for professional reasons. Beat Lüthi added: “Patrick Schär has been on the Board of Directors for 16 years. With his professional background and experience as a financial expert, he has made a significant contribution to the development of the SKAN Group. We would like to thank him sincerely for his many years of commitment and the excellent collaboration and wish him all the best for his professional and personal future.”

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead
SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs close to 1700 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.

Ad hoc announcement pursuant to Art. 53 LR

SKAN announces preliminary key figures for the 2025 financial year

Allschwil, January 26, 2026 – The SKAN Group AG, world market leader for high-quality isolator systems for aseptic production processes in the pharma and biotech industry, expects based on preliminary, not yet audited figures net sales of around CHF 332 million (2024: CHF 361.3 million) and earnings before interest, taxes, depreciation and amortization (EBITDA) of around CHF 38 million (2024: CHF 57.0 million). Order intake is expected to reach around CHF 365 million (2024: CHF 359.5 million).

Publication of the 2025 financial results:

SKAN Group AG will publish the detailed 2025 financial results on Tuesday, March 24, 2026, at 7:00 a.m. At the same time, the 2025 Annual Report and the 2025 year-end presentation will be available for download at www.skan.com. An investor, analyst and media conference is also planned for 10:00 a.m. at the Widder Hotel in Zurich. Further details will be provided in due course.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead
SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs close to 1700 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.

 Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S.

Laupheim (Germany), Milford, MA (USA), January 22, 2026 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Detra Glinatsis has rejoined the company as Head of Business Development U.S. In this newly created role, Ms. Glinatsis will lead all business development activities related to the U.S. market. She reports to Dr. Patrick Meyer, Global Head of Business Development, and is based at the company’s site in Milford, MA.

Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, commented: “I am excited to have Detra rejoin Rentschler Biopharma to serve in this important role. Her career is a true testament to her expertise, client‑centric mindset, and ability to build long‑lasting, meaningful partnerships. The United States is a cornerstone of our commercial strategy, and our presence in Milford, MA enables us to bring Rentschler Biopharma’s innovative thinking and development strength directly to the doorstep of our clients. In the past two years, we have successfully transferred one post‑PPQ[] commercial program to the site, are advancing three additional programs toward PPQ, and initiated manufacturing for six new products in 2025 – clear proof of the momentum Detra will now help to accelerate. Expanding our U.S. business is critical to the next growth stage of our corporate strategy, and Detra, with her commitment to excellence and exceeding client expectations, is the ideal person to lead our U.S. business development activities.”

Detra Glinatsis brings over twenty years of sales and business development experience in the pharmaceutical, biotech and contract manufacturing industries. She rejoins Rentschler Biopharma from Northway Biotech, where she was Vice President, Business Development. She previously held roles of increasing responsibility at AGC Biologics, Sartorius, Gallus BioPharmaceuticals, and Avecia Biologics, as well as Rentschler Biopharma, where, earlier in her career, she was Senior Director, Business Development. Ms. Glinatsis holds a B.S. in biology from the University of Akron.

Detra Glinatsis, Head of Business Development U.S., said: “I am thrilled to come back to Rentschler Biopharma as the company continues to grow its U.S. business. Together with the team, I look forward to building on the success that the company has achieved with the Milford site expansion and continuing to enhance the Rentschler Biopharma brand in the U.S. The company has a long-standing reputation for top quality and reliability, and I am excited to be working with such a talented team with a coveted track record.”

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability. For further information about the company, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn.

Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-467
communications@rentschler-biopharma.com

Media inquiries:
MC Services AG
Phone: +49-89-210228-0
rentschler@mc-services.eu

U.S.
Laurie Doyle
Phone: +1-339-832-0752

For high-resolution images, please contact communications@rentschler-biopharma.com.

^[] PPQ = Process Performance Qualification

Corporate News

Global momentum in the cannabis market: New signals from the U.S. strengthen long-term prospects for Europe and SYNBIOTIC

Düsseldorf, 21 January 2026 – The international cannabis industry is receiving new political impetus from the United States.

Trump signs executive order on cannabis reform

On 18 December 2025, the U.S. president Donald Trump signed an Executive Order directing the prompt change regarding the status of marijuana at the federal level. The U.S. federal government will reclassify marijuana from Schedule I (“highly dangerous”) to Schedule III (“less dangerous”). This is considered the biggest change in U.S. drug policy in decades.  In addition, the Executive Order took a firm and positive position as it relates to the further development and support of the U.S. based hemp industry.

What the new classification means

No complete legalisation – cannabis will remain illegal for recreational use at the federal level, but its classification and certain regulations are changing. The change is intended to facilitate the formal development of the U.S. medical cannabis sector, to facilitate participation in international cannabis commerce, and to promote medical research by lowering research barriers and improving access to clinical trials. As stated, there are further efforts to make hemp derived products, such as CBD, more accessible to the general population, and to provide reimbursements through federal programs, example such as through Medicare pilot programmes.

Reactions from industry and politics in the U.S.

Companies and stock markets reacted positively because tax burdens (including the restrictive IRS Code Section 280E) and banking problems could improve. Some conservative groups and Republican politicians have expressed concerns, particularly about public health, the risks of youth consumption, and traditional “anti-drug” positions.

Proponents see the decision as an important step toward recognising medical cannabis use, but criticise the measure for not going far enough, e.g. no decriminalisation or broader legal reforms.

Trump described the move as “common sense” and emphasised that many patients – including veterans suffering from pain – could benefit from medical cannabis. At the same time, he stressed that this did not constitute legalisation of recreational use. The decision is seen by some as a political move ahead of the 2026 midterm elections to appeal to younger and more moderate voter groups.

Although a formal decision is still pending, market participants view the latest political signals as a significant step towards a structural reassessment of the cannabis market.

International signal effect beyond the U.S.

Regardless of the specific timetable, developments in the U.S. underscore a key trend: cannabis is increasingly being viewed as a regulated health, agricultural and industrial commodity – and no longer primarily as a marginal regulatory issue.

This reassessment sends a strong signal to other markets, particularly in Europe, where regulatory processes are often driven by international considerations. International regulatory progress is particularly relevant for Germany, as Europe’s largest healthcare and pharmaceutical market. It strengthens the political and scientific momentum for medical cannabis, promotes investment in research and quality standards, and accelerates the development of a sustainable, regulated market.

SYNBIOTIC is keeping up with these developments

The latest signals from the U.S. mark another important milestone in the global development of the cannabis industry. For Europe and Germany, they increase the pressure to further harmonise regulatory frameworks and make them more innovation-friendly.

SYNBIOTIC Strategic Advisor, Robert Hoban, has been working on this issue in Washington, D.C. for a very long time, and notes that the reclassification of “Marihuana“ (as it is known under the U.S. Federal Code) will serve to open medical channels by and through the United States, and this will directly benefit internationally positioned companies, such as SYNBIOTIC.“ 

SYNBIOTIC will closely monitor all developments and continue to consistently align its own strategy with regulatory clarity, operational excellence and sustainable growth. The company considers itself well positioned to benefit from the ongoing opening of the market and an increasing political reassessment of cannabis.

Publisher

SYNBIOTIC SE

Daniel Kruse

Managing Director

Münsterstraße 336

40470 Düsseldorf

Germany

www.synbiotic.com

Media contact

Patrick Hirschauer

SYNBIOTIC Public Relations Manager

Email patrick.hirschauer@synbiotic.com

About SYNBIOTIC

SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail – from the field to shelf. The subsidiaries’ core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products. SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.

Mallia Aesthetics selected as Innovation Tank finalist at IMCAS World Congress 2026

• Mallia Aesthetics will pitch its sCD83-based cosmetic innovation competing for the “Innovation of the Year” Award
• With 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum, Mallia launched two novel solutions for consumers desiring fuller hair, eyelashes and brows
• IMCAS World Congress is an annual research conference focused on medical aesthetics with over 20,000 attendees

Erlangen, Germany, January 21, 2026 – Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, was selected to pitch as a finalist for the Innovation Tank at the IMCAS World Congress 2026, one of the largest events dedicated to dermatology, plastic surgery, and aging science held from January 29 to 31 in Paris, France. The Innovation Tank offers a global platform for start-ups to present breakthrough innovations to a high-profile jury.

During the Innovation Tank Pitch Session, scheduled for January 30 from 10:30 am – 12:30 pm, Prof. Dr. Alexander Steinkasserer will present “Soluble CD83 as a novel approach for hair growth”. The function of human soluble protein CD83 (sCD83) was first described by Prof. Steinkasserer¹, and he and his team have demonstrated its ability to activate hair growth via a multimodal mechanism of action. Based on these scientific findings, Mallia Aesthetics launched its hormone-free 8T3 Essentials Hair Serum, designed to support and enhance hair density and thickness, and 8T3 Essentials Lash & Brow Serum, formulated for promoting the growth and thickness of eyelashes and eyebrows. The 8T3 Essentials products, both based on MAL-838, a proprietary variant of sCD83, are available to consumers via Mallia’s webshop.

“Being selected as an Innovation Tank finalist further validates the translational path we have taken, from academic discovery to consumer-ready application,” said Prof. Dr. Alexander Steinkasserer, Co-founder and Managing Director of Mallia. “With our 8T3 Essentials products, we are showing how insights from immunology, particularly around soluble CD83, can be responsibly and effectively applied in aesthetic science. IMCAS offers the ideal audience to discuss both the underlying biology and the broader potential of this approach.”

The IMCAS (International Master Course on Aging Science) World 2026 Congress is a key global event dedicated to dermatology, plastic surgery, and aging science. With over 20,000 participants at the previous conference, it aims to provide physicians, including plastic surgeons, dermatologists and medical aesthetic practitioners, with the latest academic updates and provide a platform for the latest evidence-based techniques and the newest industry innovations.

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Steinkasserer. It has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth.² In addition, sCD83 has been shown to activate regulatory T cells (Tregs)³, which interact directly with hair follicles and can activate them.⁴ Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents.

Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects.

About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA^5,6).

Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications of the immunomodulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for close to 25 years by Mallia Co‑founder Prof. Dr Alexander Steinkasserer.¹

Mallia Aesthetics GmbH focuses on cosmetic applications for the stimulation of hair growth, which are also based on the scientifically validated sCD83 protein. The Company develops Innovative cosmetic products using MAL-838 that are marketed to specialists and consumers.

To purchase products from the 8T3 Essentials line, please visit our online shop: www.8T3.com

For more information, visit www.mallia.com and follow us on LinkedIn, Instagram, and Facebook.

¹ Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., … & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813

² Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., … & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

³ Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., … & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

⁴ Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., … & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

⁵ Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview

⁶ Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., … & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426

ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy

• ARTCLINE gains a prominent figure in the European biotech industry as Chairman of its Supervisory Board
• Broad market launch of ARTICE^® therapy for the treatment of immune dysfunction in septic shock scheduled for the second half of 2026

Rostock (Germany), 20 January 2026 – ARTCLINE, a biomedical company focused on the development of novel immune cell therapies for the treatment of septic shock, announces that Peter Llewellyn-Davies has joined its Supervisory Board, effective 1 January 2026 and has assumed the role of Chairman. With this appointment, the company is further advancing its commercialization strategy.

Peter Llewellyn-Davies is regarded as one of the leading personalities in the European biotechnology industry, with decades of international experience as a C-level executive, company founder, investor, and strategic advisor. As founder and CEO of Accellerate Partners, he supports management teams in growth strategies and scaling. He is also the founder and acting president of BIOTECH AUSTRIA, the Austrian biotech industry association. His career milestones include founding and managing invIOs and serving as CEO of APEIRON Biologics. Previously, he was CFO and CBO of Medigene AG and, as CFO of WILEX AG, was responsible for its IPO in 2006. Other senior positions include Executive Director of Finance, Controlling & Accounting at the Süd-Chemie Group. Peter Llewellyn-Davies is also a member of the supervisory board of Shield Therapeutics plc. The German-British citizen started his professional career at an investment bank in London.

Peter Llewellyn-Davies commented: “There is an enormous unmet medical need for septic shock therapies. Every day, more than 200 people die from this disease in Germany alone, and there are currently no adequate treatment options available. In my opinion, ARTCLINE’s ARTICE^® therapy represents a highly innovative approach and holds the potential to deliver a genuine therapeutic breakthrough: by relieving and regenerating the immune system, mortality may be reduced, particularly in the second phase of immune dysfunction. I am delighted to provide strategic support to the company as it approaches market launch.”

The impairment of the immune system plays a decisive role in the course of sepsis. Even though modern intensive care treatments can address the initial phase of septic shock, many patients subsequently die due to immune dysfunction caused by secondary infections and/or organ failure. With its patented extracorporeal ARTICE^® therapy, which uses allogeneic donor immune cells to treat immune dysfunction in septic shock, ARTCLINE GmbH is addressing this unmet medical need for the first time. The donor immune cells are purified and clinically administered under a GMP manufacturing license.

The ARTICE^® therapy is currently being evaluated in the multicenter ReActIF-ICE study (NCT05442710). The last patient is expected to be enrolled in the first quarter of 2026, with detailed results to be published at the end of 2026. The aim of the study is to validate the clinical benefit of the therapy for treating immune dysfunction in septic shock. The broad market launch of the ARTICE^® procedure is already planned for the second half of 2026, as all components of the therapy have already received regulatory approval for general use in Germany.

Dr. Jens Altrichter, Managing Director and founder of ARTCLINE GmbH, said: “We would like to thank Peter for his support and confidence in our technology. We are very proud to have gained such an internationally experienced and well-connected Chairman to our Supervisory Board, whose strategic expertise and understanding of the life sciences industry and financial markets will help to strengthen ARTCLINE in a decisive phase of its development.”

Dirk Hessel, Managing Director of ARTCLINE GmbH, commented: “I am particularly looking forward to working with Peter in view of the upcoming market launch of our ARTICE^® therapy. I am convinced that this appointment will provide us with an excellent foundation to realize the potential of this innovative and urgently needed sepsis therapy.”

About ARTCLINE GmbH

ARTCLINE GmbH develops innovative therapeutic approaches for intensive care medicine. The company focuses on a novel, immune cell-based therapy for the treatment of septic shock – one of the major challenges for global health systems.

The ARTICE^® therapy, developed in collaboration between immunologists and dialysis specialists, uses allogeneic immune cells from healthy donors to temporarily support key functions of the patient’s dysregulated immune system and help restore its activity.

For more information, please visit www.artcline.de or contact info@artcline.de. Follow ARTCLINE on LinkedIn.

Contact:       
ARTCLINE GmbH     
Dirk Hessel, Managing Director     
dirk.hessel@artcline.de     

Media inquiries:
MC Services AG
Eva Bauer / Julia von Hummel
Phone: +49-89-210228-0
artcline@mc-services.eu